At Global Voices in Renal Oncology (VIRO) 2025, organized by OncoDaily, Dr. Raquibul Hannan, Chief of the Genitourinary Radiation Oncology Service at UT Southwestern Medical Center, delivered a talk on “Radiation Approaches for Oligoprogressive RCC.”
He discussed the role of radiotherapy in oligoprogressive renal cell carcinoma (RCC) and highlighted the opportunities offered by stereotactic ablative radiotherapy (SAbR). Dr. Hannan outlined which patients benefit the most from this approach and the key parameters used to select candidates, emphasizing how SAbR can be integrated with systemic therapies. He presented study examples, including one in which he served as first author, showing that progression-free survival (PFS) with SAbR can be nearly twice as long as with radiotherapy alone.
He also reviewed ongoing clinical trials, including randomized studies, and discussed the emerging field of immunoradiotherapy, stressing the potential synergy between immunotherapy and radiotherapy in the treatment of RCC.
Join us in the conversation.